All In Biotech

Drug Trial Radar · NCT07546929

HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes

Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Feb 3, 2023

Primary completion

Oct 2026

Study completion Oct 2026

Sponsor

Lead sponsor
Housey Healthcare ULCIndustry
Sponsor type
Industry
First posted
Apr 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Blood sugar levels are controlled by insulin, a hormone made by cells in the pancreas. After a meal, carbohydrates are broken down into glucose which is absorbed from the intestine into the blood leading to a rise in glucose (blood sugar) which triggers the secretion of insulin. Insulin binds to cells in several tissues including liver, muscle, and fat, triggering cells to take up glucose and bring the blood glucose level back to normal. A high blood sugar level is known as diabetes. The most common form of diabetes, type 2 diabetes, is caused by insulin resistance; that is, a reduced ability of insulin to stimulate glucose uptake into cells. The body compensates for insulin resistance by making more insulin; type 2 diabetes occurs when the pancreas can no longer make enough insulin to control blood glucose. The high blood glucose and insulin levels lead to long-term complications such as heart attacks, kidney failure, reduced sensation and poor circulation in the feet and legs. High insulin levels also increase the incidence of cancers, stroke, and dementia. Reducing blood glucose levels with oral medications and insulin reduces risk of diabetic complications. There are several types of oral medications available for treating diabetes; however, they do not always control blood glucose adequately. In addition, these drugs have complications and are not used to treat insulin resistance and prediabetes - a condition when blood glucose is higher than normal but not high enough to be classified as diabetes. Prediabetes often progresses to diabetes over a period of months or years. Effective and safe treatments for insulin resistance may prevent the onset of diabetes or even reverse diabetes if diagnosed in its early stages before substantial damage to the pancreas has occurred. HP-211 is a botanical extract whose active ingredients are derived from herbs and vegetables present in normal diets. HP-211 has been shown in laboratory studies in cell culture, in animal studies, and in a previous Phase 1 study to enhance the ability of insulin to stimulate glucose uptake into cells. Thus, HP-211 may reduce the blood glucose and circulating insulin levels of subjects with type 2 diabetes after a meal. HP-211 may also reduce glucose and insulin responses to a greater extent in insulin-resistant as compared to insulin-sensitive subjects. Subjects will take 0, 1, 2 or 3 tablets of HP-211 in the morning and evening for 90 days. Hemoglobin A1c (HbA1c, or "A1c"), a measure of the average amount of glucose present in the blood, will be measured during the trial period.

Conditions

  • Type 2 Diabetes

Interventions

  • HP-211Drug

    HP-211 is an investigational botanical extract derived from Cichorium endivia var. latifolium, Lactuca sativa, and Artemisia dracunculus.

  • PlaceboDrug

    Matching placebo administered orally twice daily (BID).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Hemoglobin A1c (HbA1c)Time frame: After 12 weeks of treatment.

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Alliance Clinical Canoga Park (Hope Clinical Research)

    Canoga Park, California · Recruiting

  • Universal Axon Clinical Research

    Doral, Florida · Recruiting

  • Velocity Clinical Research New Smyrna Beach

    Edgewater, Florida · Recruiting

  • Southwest General Healthcare Center

    Fort Myers, Florida · Recruiting

  • Avantis Clinical Research

    Miami, Florida · Recruiting

  • IMIC Research

    Miami, Florida · Recruiting

  • South Broward Research

    Miramar, Florida · Recruiting

  • David Kavtaradze MD InC

    Cordele, Georgia · Recruiting

  • AMR Clinical - El Dorado

    El Dorado, Kansas · Recruiting

  • Tandem Clinical Research (Interspond)

    Marrero, Louisiana · Recruiting

  • Arcturus Healthcare, PLC, Troy Internal Medicine Research Division

    Troy, Michigan · Recruiting

  • Velocity Clinical Research Norfolk

    Norfolk, Nebraska · Recruiting

  • Alliance Clinical Las Vegas (Excel Clinical Research)

    Las Vegas, Nevada · Recruiting

  • Diabetes & Endocrinology Associates of Stark County, Inc.

    Canton, Ohio · Recruiting

  • Advanced Medical Research

    Maumee, Ohio · Recruiting

  • Velocity Clinical Research Providence

    East Greenwich, Rhode Island · Recruiting

  • Velocity Clinical Research Dallas

    Dallas, Texas · Recruiting

  • Tekton Research

    Irving, Texas · Recruiting

  • Alliance Clinical Lewisville (Epic Clinical Research)

    Lewisville, Texas · Recruiting

  • Tekton Research

    McKinney, Texas · Recruiting

  • Tekton Research

    San Antonio, Texas · Recruiting

  • Simcare Medical Research, LLC.

    Sugar Land, Texas · Recruiting

  • Velocity Clinical Research Waco

    Waco, Texas · Recruiting

  • Burke Internal Medicine & Research

    Burke, Virginia · Recruiting

  • Tekton Research

    Midlothian, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.